Henry L. Paulson | |
|---|---|
| Academic background | |
| Education | MD, PhD, cell biology, Yale University |
| Academic work | |
| Institutions | University of Michigan University of Iowa |
Henry Lauris Paulson is an American neurologist.
Henry L. Paulson | |
|---|---|
| Academic background | |
| Education | MD, PhD, cell biology, Yale University |
| Academic work | |
| Institutions | University of Michigan University of Iowa |
Henry Lauris Paulson is an American neurologist.
Paulson received his medical degree and doctorate in cell biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowship at the University of Pennsylvania. [1]
In 1997,Paulson joined the faculty at the University of Iowa where he established his own laboratory to describe abnormal protein aggregates in polyglutamine diseases. His lab has helped pioneer the use of gene silencing methods as a potential therapy for the many neurological disorders caused by mutant genes. [2] In 2007,Paulson left Iowa upon accepting a faculty appointment at the University of Michigan. [1]
During his tenure at the University of Michigan,Paulson has continued to explore the reasons why the aging brain degenerates in neurodegenerative diseases. [3]
He assumed directorship of the Michigan Alzheimer’s Disease Center in 2015. The Michigan Alzheimer’s Disease Center (MADC) is a National Institute of Aging-funded center dedicated to the research and understanding of Alzheimer’s disease and related dementias. Under his leadership,the MADC was the first of its kind to expand beyond its home institution to formally collaborate with two other research universities in the state,making the MADC a statewide organization. This ground-breaking initiative brought together expertise from the University of Michigan,Michigan State University,and Wayne State University to tackle the understanding of dementia in an interdisciplinary manner and extend outreach and education efforts throughout the state. [4]
In recognition of his research,Paulson was elected a Fellow of the American Association for the Advancement of Science for his efforts towards advancing science applications. [5] In 2020,he was elected to the National Academy of Medicine for his "work in making fundamental discoveries regarding protein aggregation and nucleotide repeat expansions as causes of neurodegenerative diseases,and pioneering novel therapeutic strategies,including nucleotide-based gene silencing and harnessing the cell’s own quality-control machinery,for this group of devastating disorders." [2] Following his election,Paulson was named the interim co-director of the Michigan Neuroscience Institute. [6]
A neurodegenerative disease is caused by the progressive loss of structure or function of neurons,in the process known as neurodegeneration. Such neuronal damage may ultimately involve cell death. Neurodegenerative diseases include amyotrophic lateral sclerosis,multiple sclerosis,Parkinson's disease,Alzheimer's disease,Huntington's disease,multiple system atrophy,and prion diseases. Neurodegeneration can be found in the brain at many different levels of neuronal circuitry,ranging from molecular to systemic. Because there is no known way to reverse the progressive degeneration of neurons,these diseases are considered to be incurable;however research has shown that the two major contributing factors to neurodegeneration are oxidative stress and inflammation. Biomedical research has revealed many similarities between these diseases at the subcellular level,including atypical protein assemblies and induced cell death. These similarities suggest that therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well.
Karen K. Hsiao Ashe is a professor at the Department of Neurology and Neuroscience at the University of Minnesota (UMN) Medical School,where she holds the Edmund Wallace and Anne Marie Tulloch Chairs in Neurology and Neuroscience. She is the founding director of the N. Bud Grossman Center for Memory Research and Care,and her specific research interest is memory loss resulting from Alzheimer's disease and related dementias. Her research has included the development of an animal model of Alzheimer's.
Sir John Anthony Hardy is a human geneticist and molecular biologist at the Reta Lila Weston Institute of Neurological Studies at University College London with research interests in neurological diseases.
Eva Lucille Feldman,M.D.,Ph.D.,F.A.A.N.,F.A.N.A. is an American physician-scientist and one of the world’s leading authorities on neurodegenerative disease. Currently,she serves as the Russell N. DeJong Professor of Neurology at the University of Michigan,as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also recently named the James W. Albers Distinguished University Professor of Neurology.
Steven T. DeKosky is the Aerts-Cosper Professor of Alzheimer's Research at the University of Florida (UF) College of Medicine,deputy director of UF’s Evelyn F. and William L. McKnight Brain Institute (MBI) and associate director of the 1Florida Alzheimer’s Disease Research Center.
John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner,Virginia Man-Yee Lee,MBA,Ph.D.,are noted for identifying the roles of three proteins in neurodegenerative diseases:tau in Alzheimer's disease,alpha-synuclein in Parkinson's disease,and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal degeneration.
Samuel E. Gandy,M.D.,Ph.D. is a neurologist,cell biologist,Alzheimer's disease (AD) researcher and expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. His team discovered the first drugs that could lower the formation of amyloid.
Anne Buckingham Young is an American physician and neuroscientist who has made major contributions to the study of neurodegenerative diseases,with a focus on movement disorders like Huntington's disease and Parkinson's disease. Young completed her undergraduate studies at Vassar College and earned a dual MD/PhD from Johns Hopkins Medical School. She has held faculty positions at University of Michigan and Harvard University. She became the first female chief of service at Massachusetts General Hospital when she was appointed Chief of Neurology in 1991. She retired from this role and from clinical service in 2012. She is a member of many academic societies and has won numerous awards. Young is also the only person to have been president of both the international Society for Neuroscience and the American Neurological Association.
Gladstone Institutes is an independent,non-profit biomedical research organization whose focus is to better understand,prevent,treat and cure cardiovascular,viral and neurological conditions such as heart failure,HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators,2012 Nobel Laureate Shinya Yamanaka,to improve drug discovery,personalized medicine and tissue regeneration.
The UCL Queen Square Institute of Neurology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is located in London,United Kingdom. Together with the National Hospital for Neurology and Neurosurgery,an adjacent facility with which it cooperates closely,the institute forms a major centre for teaching,training and research in neurology and allied clinical and basic neurosciences.
The Krembil Research Institute,formerly known as the Toronto Western Research Institute,is an academic medical research institute in Toronto. It is one of the largest research institutes in Canada focusing on human neurological disease.
Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology,Psychiatry,Neuroscience,and Geriatrics and Palliative Medicine at ISMMS.
Giovanna Rachele Mallucci is van Geest Professor of Clinical Neurosciences at the University of Cambridge in England and associate director of the UK Dementia Research Institute at the University of Cambridge. She is a specialist in neurodegenerative diseases.
Benjamin Wolozin is an American pharmacologist and neurologist currently at Boston University School of Medicine and an Elected Fellow of the American Association for the Advancement of Science. Benjamin Wolozin,M.D.,Ph.D. received his B.A. from Wesleyan University and his M.D.,Ph.D. from the Albert Einstein College of Medicine. He is currently a professor of Pharmacology,Neurology and the Program in Neuroscience at Boston University School of Medicine. He is also co-founder and Chief Scientific Officer (CSO) of Aquinnah Pharmaceuticals Inc.,a biotechnology company developing novel therapeutics to treat Alzheimer's disease and Amyotrophic Lateral Sclerosis.
Nancy M. Bonini is an American neuroscientist and geneticist,best known for pioneering the use of Drosophila as a model organism to study neurodegeneration of the human brain. Using the Drosophila model approach,Bonini's laboratory has identified genes and pathways that are important in the development and progression of neurodegenerative diseases such as Amyotrophic lateral sclerosis,Alzheimer's disease,and Parkinson's disease,as well as aging,neural injury and regeneration,and response to environmental toxins.
Rosa Rademakers,Ph.D.,is a neurogeneticist and professor within the Department of Neuroscience at the Mayo Clinic. Her research centers on the genetic basis of neurodegenerative diseases,such as identifying causal genes and their function,exploring familial risk factors,and the mechanism of the degeneration. Her neurodegenerative diseases of focus include "Alzheimer's disease (AD),frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)." She received a Bachelor of Arts in Biology,a Master of Arts in Biochemistry,and a Ph.D. in Science,all from the University of Antwerp. Originally from the Netherlands,she came to the Mayo Clinic in 2005 for a post-doctoral fellowship,and in 2007 she was given a lab director position.
MercèBoada y Rovira is a Catalan neurologist. She has dedicated her professional career to neurodegenerative diseases. More specifically,dementia and Alzheimer's disease. She was a co-founder of the ACE Foundation,a private non-profit entity dedicated to diagnosis,treatment,research,and helping people with Alzheimer's and their families. Boada received the "Creu de Sant Jordi",Catalonia's highest honor,in 2016.
Dennis J. Selkoe is an American physician (neurologist) known for his research into the molecular basis of Alzheimer's disease. In 1985 he became Co-Director of the Center for Neurological Diseases and from 1990,Vincent and Stella Coates Professor of Neurological Diseases at Harvard Medical School. He is also a Fellow of the AAAS and a member of the National Academy of Medicine.
Gerard David Schellenberg is an academic neuropathologist who specializes in the research of Alzheimer's disease. He is the director of Penn Neurodegeneration Genomics Center as well as a professor of Pathology and Laboratory Medicine at the University of Pennsylvania. He is a leading contributor to Alzheimer's disease research.
Keenan A. Walker,Ph.D.,directs the Multimodal Imaging of Neurodegenerative Disease unit in the Laboratory of Behavioral Neuroscience at the National Institute on Aging. His research includes studies on Alzheimer's disease.
Henry L. Paulson publications indexed by Google Scholar